Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 7, 2016, Pages 1975-1981

  Rojas, Jhon ^a   Blanco, José L ^a   Marcos, María A ^a   Lonca, Montserrat ^a   Tricas, Amparo ^a   Moreno, Laura ^a   Gonzalez Cordon, Ana ^a   Torres, Berta ^a   Mallolas, Josep ^a   Garcia, Federico ^b   Gatell, Jose M ^a   Martinez, Esteban ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; C REACTIVE PROTEIN; CHOLESTEROL; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LIPID; LOPINAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE URINE LEVEL; DIGESTIVE SYSTEM DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; ADVERSE EFFECTS; HIV INFECTIONS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PROCEDURES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIROLOGY;

FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 84979067018     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw078     Document Type: Article

References (24)

1. Solomon DA, Sax PE. Current state and limitations of daily oral therapy for treatment. Curr Opin HIV AIDS 2015; 10: 219-25
2. Winston A, Underwood J. Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection. Curr Opin Infect Dis 2015; 28: 17-22
3. Turriziani O, Andreoni M, Antonelli G. Resistant variants in cellular reservoirs of human immunodeficiency virus infection. Clin Microbiol Infect 2010; 16: 1518-24
4. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos con infección por el virus de la inmunodeficiencia humana (Actualización enero 2015). http://www.gesida-seimc.org/contenidos/guiasclinicas/2015/gesida-guiasclinicas-2015-tar.pdf
5. European AIDS Clinical Society. Guidelines, Version 8.0, October 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8.0-english_revised-20151104.pdf
6. Clumeck N, Hill A, MoecklinghoffC. Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events. AIDS Rev 2014; 16: 236-45
7. Paton NI, Stöhr W, Arenas-Pinto A et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV 2015; 2: e-417-26
8. Martinez E, Gatell JM. Position of dolutegravir in the treatment of HIV infection. Enferm Infecc Microbiol Clin 2015; 33 Suppl 1: 31-3
9. Orden SAS/3470/2009, de 16 de diciembre, por la que se publican las directrices sobre estudios posautorización de tipo observacional para medicamentos de uso humano. https://www.boe.es/diario_boe/txt.php?id=BOEA-2009-20817
10. Pugliese P, Delpierre C, Cuzin L et al. An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. HIV Med 2013; 14: 509-15
11. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18
12. Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31
13. RaffiF, Jaeger H, Quiros-Roldan E et al. 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13: 927-35
14. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8
15. Kobayashi M, Yoshinaga T, Seki T et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21
16. van Lunzen J, Maggiolo F, Arribas JR et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12: 111-8
17. Katlama C, Soulié C, Blanc C et al. Dolutegravir monotherapy in HIV-infected patients with suppressed viremia. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract PS 4/4
18. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207: 740-8
19. Quashie PK, Mesplède T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705
20. Mesplède T, Quashie PK, Osman N et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013; 10: 22
21. Figueroa MI, Sued O, Patterson P et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. In: Abstracts of the Fifteenth European AIDS Conference, Spain, 2015. Abstract LBPS 4/1
22. Gubavu C, Prazuck T, NiangMet al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother 2016; 71: 1046-50
23. ViiV Healthcare Begins Phase III ProgrammeWith Dolutegravir/Rilpivirine Combination For HIV Maintenance Therapy. https://www.viivhealthcare.com/media/press-releases/2015/may/viiv-healthcare-begins-phase-iiiprogramme-with-dolutegravirrilpivirine-combination-for-hiv-maintenancetherapy.aspx
24. Carr A, Hoy J, Pozniak A. The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior? PLoS Med 2012; 9: e1001240